fashion -WSS

fashion

author：explore 2025-08-12 08:27:29 - browse：427

Johnson & Johnson sign — MARK RALSTON/AFP via Getty Images

WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.

J&J joins a flurry of litigation challenging the Medicare drug price negotiation program, which is set to start this fall. Merck, Bristol Myers Squibb, the brand-drug lobby PhRMA, and the U.S. Chamber of Commerce have also filed suit. The negotiated prices would go into effect in 2026.

The company argued that it is entitled to sue because its blockbuster blood thinner drug Xarelto may be up for negotiation in the first round of ten drugs Medicare will examine, but that list is not set to be announced officially until Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： #NeedHerScience: shining a light on gender disparities in medicine

knowledge

WSS

Cloning humans is technically possible. It's curious no one has tried

Roche subsidiary Foundation Medicine opens new headquarters

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Primary care physicians play key roles in Alzheimer's management

Disclosing genetic information: not as worrisome as once feared

Will generative AI in health care meet the fate of IBM's Dr. Watson?

focus

fashion

explore

Moonlake's readout produced a cash windfall. Risks remain

The strategy behind pharma's lawsuits over drug pricing reform

Moonlake's readout produced a cash windfall. Risks remain

Supreme Court mifepristone arguments center on docs' right to sue

FDA approval of Sarepta Duchenne genetic therapy gives me hope

There's no autism epidemic. It's an autism diagnosis epidemic

United colonoscopy coverage change 'may cost lives,' doctors say

Colonoscopy at 40? Study finds a possible benefit

Duchenne breakthrough therapy leaves behind pioneering families

The battle over the Brookhaven Landfill on Long Island

hotspot

The Readout: Lenmeldy, GLP

Why the world’s most expensive drug might be worth the price

Readout LOUD podcast: mifepristone case, GLP

Vertex Pharmaceuticals may move headquarters in Boston

In areas with more Black doctors, Black people live longer

In areas with more Black doctors, Black people live longer

knowledge

hotspot

hotspot

leisure time